Lecanemab is an anti-amyloid monoclonal antibody medication that targets the deposits or plaques of amyloid beta proteins in the brain.
Alzheimer's can be prevented if you start exercising your brain nerves much earlier say docs. (Wikimedia Commons)
Cardiologists are advocating for additional research on the drug Lecanemab that can add to the limited safety data, currently used for decision-making before initiating treatment of Alzheimer’s disease. Initially granted an “accelerated approval” in January 2023, Lecanemab received full approval from the FDA for the treatment of mild cognitive impairment or early dementia due to Alzheimer’s disease on 6 July last year.